In­vestors are pump­ing more mon­ey in­to one of the mi­cro­bio­me field’s longest-stand­ing biotechs to push it to­ward a Phase 3 read­out in C. dif­fi­cile next …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
Think we're worth reading - tell Google.
Confirm Endpoints as a trusted biopharma news source